MAP2K1 and non-small cell lung carcinoma: In several phase II and III trials, MEK1/2 inhibitor monotherapies failed to drive significant improvements in response rates or overall survival when compared with standard chemotherapy in patients with KRAS-mutant NSCLC (15, 16).